Effects of the Addition of Mosapride to Gastroesophageal Reflux Disease Patients on Proton Pump Inhibitor: A Prospective Randomized, Double-blind Study.
- Author:
Hyun Chul LIM
1
;
Jie Hyun KIM
;
Young Hoon YOUN
;
Eun Hee LEE
;
Byung Keon LEE
;
Hyojin PARK
Author Information
1. Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. hjpark21@yuhs.ac
- Publication Type:Randomized Controlled Trial ; Original Article
- Keywords:
Gastric emptying;
Gastroesophageal reflux;
Mosapride;
Proton pump inhibitors
- MeSH:
2-Pyridinylmethylsulfinylbenzimidazoles;
Benzamides;
Cholecystokinin;
Double-Blind Method*;
Fasting;
Gastric Acid;
Gastric Emptying;
Gastrins;
Gastroesophageal Reflux*;
Humans;
Morpholines;
Nausea;
Plasma;
Prospective Studies*;
Proton Pump Inhibitors*;
Surveys and Questionnaires
- From:Journal of Neurogastroenterology and Motility
2013;19(4):495-502
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: Proton pump inhibitors (PPIs) which are the most effective agents for the treatment of gastroesophageal reflux disease (GERD), have been known to delay gastric emptying. Mosapride has been used as prokinetics by accelerating gastric emptying. We evaluated the efficacy of mosapride to prevent PPI-induced delayed gastric emptying in a prospective randomized, double-blind and placebo-controlled trial. METHODS: Thirty patients who were diagnosed as GERD and had normal gastric emptying were included in this study. PPI monotherapy group was treated with placebo drug in addition to pantoprazole and PPI plus mosapride group was treated with mosapride in addition to pantoprazole for 8 weeks. Gastric emptying scan and questionnaires about GERD and dyspeptic symptoms were assessed by scoring before and after treatment. To evaluate the changes of gastrointestinal endocrine hormones by PPI which are associated gastric acid secretion and gastric motility, fasting plasma gastrin and cholecystokinin were taken at weeks 0 and 8. RESULTS: Half gastric emptying time was increased (P = 0.023) in PPI monotherapy group, and there were no significant changes in PPI plus mosapride group. Plasma gastrin level increased in PPI monotherpay group (P = 0.028) and there were no significant changes in PPI plus mosapride group. Plasma cholecystokinin level was not changed after treatment in both groups. GERD symptoms were improved after treatment in both groups, and postprandial bloating and nausea were improved in PPI plus mosapride group. CONCLUSIONS: Mosapride showed to be effective in preventing delayed gastric emptying and the increase in plasma gastrin level induced by PPI treatment, but did not show prominent clinical symptom improvements.
